Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease

Por van Dussen, Laura, Biegstraaten, Marieke, Hollak, Carla EM, Dijkgraaf, Marcel GW
Publicado em 2014

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications

Por van Dussen, Laura, Biegstraaten, Marieke, Dijkgraaf, Marcel GW, Hollak, Carla EM
Publicado no Orphanet J Rare Dis (2014)

Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage

Por Bohte, Anneloes E., van Dussen, Laura, Akkerman, Erik M., Nederveen, Aart J., Sinkus, Ralph, Jansen, Peter L. M., Stoker, Jaap, Hollak, Carla E. M.
Publicado em 2013

Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes

Por van Dussen, Laura, Cox, Timothy M., Hendriks, Erik J., Morris, Elizabeth, Akkerman, Erik M., Maas, Mario, Groener, Johanna E. M., Aerts, Johannes M.F.G., Deegan, Patrick B., Hollak, Carla E. M.
Publicado em 2012

Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response

Por Dekker, Nick, van Dussen, Laura, Hollak, Carla E. M., Overkleeft, Herman, Scheij, Saskia, Ghauharali, Karen, van Breemen, Mariëlle J., Ferraz, Maria J., Groener, Johanna E. M., Maas, Mario, Wijburg, Frits A., Speijer, Dave, Tylki-Szymanska, Anna, Mistry, Pramod K., Boot, Rolf G., Aerts, Johannes M.
Publicado em 2011